Jayson Rieger

CIK: 0002043558

Transaction Breakdown

Open Market Buys (P)4 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (37.5%)

Compensation grants

Other (G, F, J, C, D, …)1 (12.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VRCA

Verrica Pharmaceuticals Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

VRCA
Verrica Pharmaceuticals Inc.
Aug 17, 2026
Purchase(P)
Direct
5K shares at avg. $4.91$25K
VRCA
Verrica Pharmaceuticals Inc.
Aug 14, 2026
Purchase(P)
Direct
20K shares at avg. $5.06$101K
VRCA
Verrica Pharmaceuticals Inc.
Jun 5, 2026
Award(A)
Employee Stock Option (right to buy)
Direct
512.3K shares-
VRCA
Verrica Pharmaceuticals Inc.
Nov 25, 2025
Purchase(P)
Direct
94.3K shares at avg. $4.24$400K
VRCA
Verrica Pharmaceuticals Inc.
Mar 14, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
850K shares-
VRCA
Verrica Pharmaceuticals Inc.
Nov 26, 2024
Gift(G)
Direct
50K shares-
VRCA
Verrica Pharmaceuticals Inc.
Nov 22, 2024
Purchase(P)
Direct
280.9K shares-
VRCA
Verrica Pharmaceuticals Inc.
Nov 6, 2024
Award(A)
Employee Stock Option (right to buy)
Direct
2M shares-

		Type	Shares	Price		Ownership
Aug 17, 2026	VRCA Verrica Pharmaceuticals Inc.	Purchase(P)	5,000	$4.91	$24,550	Direct
Aug 14, 2026	VRCA Verrica Pharmaceuticals Inc.	Purchase(P)	20,000	$5.06	$101,200	Direct
Jun 5, 2026	VRCA Verrica Pharmaceuticals Inc.	Award(A) Employee Stock Option (right to buy)	512,269	-	-	Direct
Nov 25, 2025	VRCA Verrica Pharmaceuticals Inc.	Purchase(P)	94,311	$4.24	$400,114	Direct
Mar 14, 2025	VRCA Verrica Pharmaceuticals Inc.	Award(A) Employee Stock Option (right to buy)	850,000	-	-	Direct
Nov 26, 2024	VRCA Verrica Pharmaceuticals Inc.	Gift(G)	50,000	-	$0	Direct
Nov 22, 2024	VRCA Verrica Pharmaceuticals Inc.	Purchase(P)	280,898	-	$0	Direct
Nov 6, 2024	VRCA Verrica Pharmaceuticals Inc.	Award(A) Employee Stock Option (right to buy)	2,000,000	-	-	Direct

1-8 of 8 transactions

About Rieger Jayson

Rieger Jayson (SEC CIK 0002043558) files insider reports with the SEC as CEO and President of Verrica Pharmaceuticals Inc. (VRCA).

Signal8 holds 7 ownership filings by Rieger Jayson (1 Form 3, 6 Form 4), filed between Nov 6, 2024 and Aug 18, 2026. Those filings report 8 transactions, from Nov 6, 2024 to Aug 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Rieger Jayson's filings is in WEST CHESTER, PA.

Recent filings by Rieger Jayson

Aug 17, 2026: Open-market purchase of VRCA shares (Form 4, code P).
Aug 14, 2026: Open-market purchase of VRCA shares (Form 4, code P).
Jun 5, 2026: Grant or award of VRCA derivative securities (Form 4, code A).
Nov 25, 2025: Open-market purchase of VRCA shares (Form 4, code P).
Mar 14, 2025: Grant or award of VRCA derivative securities (Form 4, code A).

Other insiders filing for Verrica Pharmaceuticals Inc. (VRCA)

Zawitz David, Chief Operating Officer
Rosenberg Noah L., CMO
Kirby John J., Interim CFO
Eichenfield Lawrence, Director
Nguyen Diem, Director
PRYGOCKI MARK A SR, Director

How to read Form 4 transaction codes